Clinical lymphoma, myeloma & leukemia · 2026
Pseudo-Richter Transformation Following BTKi Interruption in CLL: A Systematic Review of Clinical, Biological, and Pathologic Features.
Клинический случайСтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marco-Ayala Javier, García Malo María Dolores, Ortuño Francisco J, Lozano María Luisa
Аннотация
BACKGROUND: Pseudo-Richter transformation (pseudo-RT) is a rare and recently recognized phenomenon characterized by a transient large B-cell proliferation occurring shortly after interruption of Bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL). Although it closely mimics true Richter transformation (RT) clinically and histologically, pseudo-RT follows a distinct and reversible course, and its recognition is essential to avoid misdiagnosis and inappropriate treatment.
METHODS: We report a new case of pseudo-RT with circulating large atypical cells and present a systematic review of published cases.
RESULTS: Fifteen cases were identified. The median age at pseudo-RT onset was 72 years, and 87% of patients were male. All analyzed CLL IGHV sequences were unmutated (5/5 tested). Trisomy 12 was the most frequent cytogenetic abnormality (7/9, 78%), and TP53 disruption was present in 6 patients, including del(17p) and TP53 mutations. Pseudo-RT typically developed 3 to 13 days after BTKi interruption and most cases presented with lymphadenopathy, B symptoms, lymphocytosis, and elevated lactate dehydrogenase levels. Histological examination consistently demonstrated diffuse large B-cell proliferations with high Ki-67 expression (50-90%) and retained expression of CD5 and CD23, with a non-germinal center B-cell phenotype in all evaluable cases (9/9). Reintroduction of BTKi therapy resulted in complete clinical, laboratory, and radiologic resolution in all patients. No cases of subsequent RT were reported during follow-up (3-36 months).
CONCLUSION: pseudo-RT is a reversible event, and awareness of its characteristic features is essential to prevent overtreatment.
METHODS: We report a new case of pseudo-RT with circulating large atypical cells and present a systematic review of published cases.
RESULTS: Fifteen cases were identified. The median age at pseudo-RT onset was 72 years, and 87% of patients were male. All analyzed CLL IGHV sequences were unmutated (5/5 tested). Trisomy 12 was the most frequent cytogenetic abnormality (7/9, 78%), and TP53 disruption was present in 6 patients, including del(17p) and TP53 mutations. Pseudo-RT typically developed 3 to 13 days after BTKi interruption and most cases presented with lymphadenopathy, B symptoms, lymphocytosis, and elevated lactate dehydrogenase levels. Histological examination consistently demonstrated diffuse large B-cell proliferations with high Ki-67 expression (50-90%) and retained expression of CD5 and CD23, with a non-germinal center B-cell phenotype in all evaluable cases (9/9). Reintroduction of BTKi therapy resulted in complete clinical, laboratory, and radiologic resolution in all patients. No cases of subsequent RT were reported during follow-up (3-36 months).
CONCLUSION: pseudo-RT is a reversible event, and awareness of its characteristic features is essential to prevent overtreatment.